Tag

Phase 3

All articles tagged with #phase 3

Novavax's COVID-Influenza Vaccine Candidates Demonstrate Strong Immune Response in Phase 3 Trial

Originally Published 7 months ago — by Novavax

Featured image for Novavax's COVID-Influenza Vaccine Candidates Demonstrate Strong Immune Response in Phase 3 Trial
Source: Novavax

Novavax announced that its COVID-19-Influenza combination and stand-alone influenza vaccines elicited strong immune responses and were well tolerated in a Phase 3 trial involving adults aged 65 and older, with results comparable to existing licensed vaccines, supporting further development and potential partnerships.

Novavax's COVID-Influenza Vaccine Candidates Demonstrate Strong Immune Response in Phase 3 Trial

Originally Published 7 months ago — by Novavax Investor Relations

Featured image for Novavax's COVID-Influenza Vaccine Candidates Demonstrate Strong Immune Response in Phase 3 Trial
Source: Novavax Investor Relations

Novavax announced that its COVID-19-Influenza combination and stand-alone influenza vaccines elicited strong immune responses and were well tolerated in a Phase 3 trial involving adults aged 65 and older, with results comparable to existing licensed vaccines, supporting further development and partnership discussions.

"Insider Insights: WoW Season of Discovery Phase 3 Highlights and Controversies"

Originally Published 1 year ago — by Dexerto

Featured image for "Insider Insights: WoW Season of Discovery Phase 3 Highlights and Controversies"
Source: Dexerto

World of Warcraft's Season of Discovery Phase 3 is live, with the development team addressing issues such as unexpected buffs, tuning adjustments, and missing loot in dungeons. The Sunken Temple raid and Nightmare Incursions are proving challenging for players, with the final encounter against the Avatar of Hakkar causing difficulty. Despite some issues, the phase has had a successful start, and players are able to engage in new PvE activities and content.

"Unveiling WoW Classic's Season of Discovery Phase 3: Level Cap Raised, New Runes, Raid, and the Unruly Emerald Dream"

Originally Published 1 year ago — by PC Gamer

Featured image for "Unveiling WoW Classic's Season of Discovery Phase 3: Level Cap Raised, New Runes, Raid, and the Unruly Emerald Dream"
Source: PC Gamer

WoW Classic's Season of Discovery phase 3 is now live, featuring a raised level cap to 50, 54 new runes, and a 20-player raid in the Sunken Temple. The update also introduces Nightmare Incursions, allowing players to venture into the corrupted Emerald Dream. Additionally, an improved Discoverer's Delight provides XP boosts for players. To access the new content, players need an active subscription on a World of Warcraft account.

"Balancing Act: Evaluating the Impact of New EPA Rules on Heavy-Duty Vehicles and Electric Truck Sales"

Originally Published 1 year ago — by U.S. EPA.gov

Featured image for "Balancing Act: Evaluating the Impact of New EPA Rules on Heavy-Duty Vehicles and Electric Truck Sales"
Source: U.S. EPA.gov

The U.S. EPA has announced a final rule, "Greenhouse Gas Emissions Standards for Heavy-Duty Vehicles – Phase 3," to reduce greenhouse gas emissions from heavy-duty vehicles starting in model year 2027. The standards will apply to vocational vehicles and tractors, building on the 2016 Heavy-Duty Phase 2 program with a flexible, technology-neutral, and performance-based approach, allowing manufacturers to choose emissions control technologies that best suit their needs and those of their customers.

"Pridopidine Phase 3 Trial for ALS Patients Expected This Year"

Originally Published 1 year ago — by ALS News Today

Featured image for "Pridopidine Phase 3 Trial for ALS Patients Expected This Year"
Source: ALS News Today

Prilenia Therapeutics plans to launch a pivotal Phase 3 study of pridopidine, a potential amyotrophic lateral sclerosis (ALS) treatment, following promising Phase 2 trial data showing slower disease progression, improved quality of life, and potential survival prolongation in early-stage ALS patients. Pridopidine, designed to activate the sigma-1 receptor, aims to slow ALS progression by boosting nerve cell function and survival. While the Phase 2/3 trial did not meet its main goal, pridopidine showed significant improvements in speech measures and slowed declines in respiratory function and overall life quality, particularly in early, fast-progressing ALS patients. Pridopidine was well tolerated, and its continued development is supported by an ongoing expanded access program and orphan drug designation in the U.S. and Europe.